Patient info Search Menu

Voriconazole Hikma 200 mg powder for solution for infusion – patient leaflet, side effects, dosage

Updated:
Medicine strength:
200 mg
Contains active substance:

Patient leaflet - Voriconazole Hikma 200 mg powder for solution for infusion

1. WHAT VORICONAZOLE IS AND WHAT IT IS USED FOR

  • Ritonavir (used for treating HIV) in doses of 100 mg twice daily
  • Glasdegib (used for treating cancer) – if you need to use both drugs your

Voriconazole contains the active substance voriconazole. Voriconazole is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.

doctor will monitor your heart rhythm frequently

Tell your doctor if you are taking either of the following medicines, as treatment with Voriconazole at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:

It is used for the treatment of patients (adults and children over the age of 2) with:

  • Rifabutin (used for treating tuberculosis). If you are already being treated
  • invasive aspergillosis (a type of fungal infection due to Aspergillus sp.),

    with rifabutin, your blood counts and side effects to rifabutin will need to be monitored.

  • candidaemia (another type of fungal infection due to Candida sp.) in

    non-neutropenic patients (patients without abnormally low white blood cell count),

  • Phenytoin (used to treat epilepsy). If you are already being treated with

    phenytoin, your blood concentration of phenytoin will need to be monitored during your treatment with Voriconazole and your dose may be adjusted.

  • serious invasive Candida sp. infections when the fungus is resistant to

    fluconazole (another antifungal medicine),

  • serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two

    Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/or Voriconazole are still having the desired effect:

    different species of fungi).

Voriconazole is intended for patients with worsening, possibly life-threatening, fungal infections.

  • Warfarin and other anticoagulants (e.g. phenprocoumon, acenocoumarol;

    used to slow down clotting of the blood)

Prevention of fungal infections in high risk bone marrow transplant recipients.

  • Ciclosporin (used in transplant patients)
  • Tacrolimus (used in transplant patients)

This medicinal product should only be used under the supervision of a doctor.

  • Sulfonylureas (e.g., tolbutamide, glipizide and glyburide) (used for diabetes)

2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VORICONAZOLE

  • Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)
  • Benzodiazepines (e.g., midazolam, triazolam) (used for severe insomnia and

    stress)

  • Omeprazole (used for treating ulcers)

Do not take Voriconazole:

  • Oral contraceptives (if you take Voriconazole whilst using oral
  • If you are allergic to the active ingredient voriconazole or to sulfobutylether

    contraceptives, you may get side effects such as nausea and menstrual disorders)

    beta cyclodextrin sodium (listed in section 6).

  • Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)

It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.

  • Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib,

    cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (used for treating cancer)

  • Tretinoin (used to treat leukaemia)

The medicines in the following list must not be taken during your Voriconazole treatment:

  • Indinavir and other HIV protease inhibitors (used for treating HIV)
  • Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine,

    nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as Voriconazole)

  • Terfenadine (used for allergy)
  • Astemizole (used for allergy)
  • Methadone (used to treat heroin addiction)
  • Cisapride (used for stomach problems)
  • Alfentanil and fentanyl and other short acting opiates such as sufentanil
  • Pimozide (used for treating mental illness)

    (painkillers used for surgical procedures)

  • Quinidine (used for irregular heart beat)
  • Oxycodone and other long acting opiates such as hydrocodone (used for
  • Ivabradine (used for symptoms of chronic heart failure)

    moderate to severe pain)

  • Rifampicin (used for treating tuberculosis)
  • Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for
  • Efavirenz (used for treating HIV) in doses of 400 mg and above once daily

    treating pain and inflammation)

  • Carbamazepine (used to treat seizures)
  • Fluconazole (used for treating fungal infections)
  • Phenobarbital (used for severe insomnia and seizures)
  • Everolimus (used for treating advanced kidney cancer and in transplant
  • Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)

    patients)

  • Sirolimus (used in transplant patients)
  • Letermovir (used for preventing cytomegalovirus (CMV) disease after bone
  • Ritonavir (used for treating HIV) in doses of 400 mg and more twice daily

    marrow transplant)

  • St John’s Wort (herbal supplement)
  • Mavacamten (used to treat adults with a type of heart disease called
  • Naloxegol (used to treat constipation specifically caused by pain medicines,

    obstructive hypertrophic cardiomyopathy)

    called opioids, (e.g., morphine, oxycodone, fentanyl, tramadol, codeine))

  • Ivacaftor (used to treat cystic fibrosis)
  • Tolvaptan (used to treat hyponatremia (low levels of sodium in your blood)
  • Flucloxacillin (antibiotic used against bacterial infections)

or to slow kidney function decline in patients with polycystic kidney disease)

  • Lurasidone (used to treat depression)

    Pregnancy and breast-feeding

  • Finerenone (used to treat chronic kidney disease)

    Voriconazole must not be used during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while being treated with Voriconazole.

  • Eplerenone (used to treat heart and/or blood vessel problems)
  • Voclosporin (used to treat immune disorders)
  • Venetoclax (used to treat patients with chronic lymphocytic leukaemia-CLL)

Warnings and precautions

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Talk to your doctor, pharmacist or nurse before taking Voriconazole if:

  • You have had an allergic reaction to other azoles.
  • You are suffering from, or have ever suffered from liver disease. If you have

    Driving and using machines

    liver disease, your doctor may prescribe a lower dose of Voriconazole. Your doctor should also monitor your liver function while you are being treated with Voriconazole by doing blood tests.

    Voriconazole may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Tell your doctor if you experience this.

  • You are known to have cardiomyopathy, irregular heart beat, slow heart

    rate or an abnormality of electrocardiogram (ECG) called ‘long QTc syndrome’.

    Voriconazole contains sodium

    This medicine contains 217.6 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 10.9% of the recommended maximum daily dietary intake of sodium for an adult.

You should avoid any sunlight and sun exposure while being treated. It is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun’s UV rays can occur. This may be further increased by other medicines that sensitise the skin to sunlight, like methotrexate. These precautions are also applicable to children.

Voriconazole contains cyclodextrins

This medicine contains 3200 mg cyclodextrins in each vial which is equivalent to 160 mg/ml when reconstituted in 20 ml. If you have a kidney disease, talk to your doctor before you receive this medicine.

While being treated with Voriconazole:

3. HOW TO TAKE VORICONAZOLE

  • Tell your doctor immediately if you develop

    • sunburn
    • severe skin rash or blisters

      Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

    • bone pain.

If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis. There is a small chance that skin cancer could develop with long term use of Voriconazole.

Your doctor will determine your dose depending on your weight and the type of infection you have.

Your doctor may change your dose depending upon your condition.

If you develop signs of ‘adrenal insufficiency’ where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol which may lead to symptoms such as: chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, please tell your doctor.

Intravenous

Dose for the first 24 hours

(Loading Dose)

6 mg/kg every 12 hours for the first 24 hours

If you develop signs of ‘Cushing’s syndrome’ where the body produces too much of the hormone cortisol which may lead to symptoms such as: weight gain, fatty hump between the shoulders, a rounded face, darkening of the skin on the stomach, thighs, breasts, and arms, thinning skin, bruising easily, high blood

Dose after the first 24 hours

(Maintenance Dose)

4 mg/kg twice a day

Depending on your response to treatment, your doctor may decrease the dose to 3 mg/kg twice daily.

The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.

Use in children and adolescents

The recommended dose for children and teenagers is as follows:

Intravenous

Children aged 2 to less than 12 years and

teenagers aged 12 to 14 years weighing less than 50 kg

Teenagers aged 12 to 14 years weighing 50 kg or more; and all teenagers older than 14

Dose for the first 24 hours

(Loading Dose)

9 mg/kg every 12 hours for the first 24 hours6 mg/kg every 12 hours for the first 24 hours
Dose after the first 24 hours (Maintenance Dose)8 mg/kg twice a day4 mg/kg twice a day

Depending upon your response to treatment, your doctor may increase or decrease the daily dose.

Voriconazole powder for solution for infusion will be reconstituted and diluted to the correct concentration by your hospital pharmacist or nurse. (Please refer to the end of this leaflet for further information).

This will be given to you by intravenous infusion (into a vein) at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.

If you or your child are taking Voriconazole for prevention of fungal infections, your doctor may stop giving Voriconazole if you or your child develop treatment related side effects.

If a dose of Voriconazole has been forgotten:

As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However, tell your doctor or pharmacist if you think that a dose has been forgotten.

If you stop taking Voriconazole

Voriconazole treatment will continue for as long as your doctor advises, however the duration of treatment with voriconazole should be no more than 6 months.

Patients with a weakened immune system or those with difficult infections may require long term treatment to prevent the infection from returning. You may be switched from the intravenous infusion to tablets once your condition improves.

When Voriconazole treatment is stopped by your doctor you should not experience any effects.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.

Serious side effects – Stop taking Voriconazole and see a doctor immediately

  • Rash
  • Jaundice; changes in blood tests of liver function
  • Pancreatitis

Other side effects include:

Very common: may affect more than 1 in 10 people

  • Visual impairment (change in vision including blurred vision, visual color

    alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes)

  • Fever
  • Rash
  • Nausea, vomiting, diarrhoea
  • Headache
  • Swelling of the extremities
  • Stomach pains
  • Breathing difficulties.
  • Elevated liver enzymes

Common: may affect up to 1 in 10 people

  • Inflammation of the sinuses, inflammation of the gums, chills, weakness
  • Low numbers of some types, including severe, of red (sometimes

    immune-related) and/or white blood cells (sometimes with fever), low numbers of cells called platelets that help blood to clot

  • Low blood sugar, low blood potassium, low sodium in the blood
  • Anxiety, depression, confusion, agitation, inability to sleep, hallucinations
  • Seizures, tremors or uncontrolled muscle movements, tingling or abnormal

    skin sensations, increase in muscle tone, sleepiness, dizziness

  • Bleeding in the eye
  • Heart rhythm problems including very fast heartbeat, very slow heartbeat,

    fainting

  • Low blood pressure, inflammation of a vein (which may be associated with

    the formation of a blood clot)

  • Acute breathing difficulty, chest pain, swelling of the face (mouth, lips and

    around eyes), fluid accumulation in the lungs

  • Constipation, indigestion, inflammation of the lips
  • Jaundice, inflammation of the liver and liver injury
  • Skin rashes which may lead to severe blistering and peeling of the skin

    characterized by a flat, red area on the skin that is covered with small confluent bumps, redness of the skin

  • Itchiness
  • Hair loss
  • Back pain
  • Kidney failure, blood in the urine, changes in kidney function tests.
  • Sunburn or severe skin reaction following exposure to light or sun
  • Skin cancer

Uncommon: may affect up to 1 in 100 people

  • Flu-like symptoms, irritation and inflammation of the gastrointestinal tract,

    inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels

  • Inflammation of the thin tissue that lines the inner wall of the abdomen

    and covers the abdominal organs

  • Enlarged lymph glands (sometimes painful), failure of blood marrow,

    increased eosinophil

  • Depressed function of the adrenal gland, underactive thyroid gland

    • Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet
    • Problems with balance or coordination
    • Swelling of the brain
    • Double vision, serious conditions of the eye including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling
    • Decreased sensitivity to touch
    • Abnormal sense of taste
    • Hearing difficulties, ringing in the ears, vertigo
    • Inflammation of certain internal organs- pancreas and duodenum, swelling and inflammation of the tongue
    • Enlarged liver, liver failure, gallbladder disease, gallstones
    • Joint inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot)
    • Inflammation of the kidney, proteins in the urine, damage to the kidney
    • Very fast heart rate or skipped heartbeats, sometimes with erratic electrical impulses
    • Abnormal electrocardiogram (ECG)
    • Blood cholesterol increased, blood urea increased
    • Allergic skin reactions (sometimes severe), including life-threatening skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth, inflammation of the skin, hives, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema
    • Infusion site reaction
    • Allergic reaction or exaggerated immune response
    • Inflammation of the tissue surrounding the bone

Rare: may affect up to 1 in 1000 people

  • Overactive thyroid gland
  • Deterioration of brain function that is a serious complication of liver disease
  • Loss of most fibers in the optic nerve, clouding of the cornea, involuntary movement of the eye
  • Bullous photosensitivity
  • A disorder in which the body’s immune system attacks part of the peripheral nervous system
  • Heart rhythm or conduction problems that (sometimes life threatening)
  • Life threatening allergic reaction
  • Disorder of blood clotting system
  • Allergic skin reactions (sometimes severe), including rapid swelling

    (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or sore patches of thick, red skin with silvery scales of skin, irritation of the skin and mucous membranes, life-threatening skin condition that causes large portions of the epidermis, the skin's outermost layer, to detach from the layers of skin below

  • Small dry scaly skin patches, sometimes thick with spikes or ‘horns’

Side effects with frequency not known:

  • Freckles and pigmented spots

Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:

  • Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called cutaneous lupus erythematosus

Reactions during the infusion have occurred uncommonly with Voriconazole (including flushing, fever, sweating, increased heart rate and shortness of breath). Your doctor may stop the infusion if this occurs.

As Voriconazole has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidneys by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.

There have been reports of skin cancer in patients treated with voriconazole for long periods of time

Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis. Elevated liver enzymes were also observed more frequently in children.

If any of these side effects persist or are troublesome, please tell your doctor.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE VORICONAZOLE

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Voriconazole contains

  • The active substance is voriconazole. Each vial contains 200 mg voriconazole, equivalent to 10 mg/ml solution when reconstituted as directed by your hospital pharmacist or nurse.
  • The other ingredient is sulfobutylether beta cyclodextrin sodium.

What Voriconazole looks like and contents of the pack

Voriconazole is a white to off-white lyophilised cake.

Voriconazole is presented in packs of 1 or 5 glass vials as a powder for solution for infusion. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Hikma Farmacêutica (Portugal), S.A.

Estrada do Rio da Mó n.º 8, 8A e 8B, Fervença

2705-906 Terrugem SNT

Portugal

Manufacturer

Hikma Italia S.p.A.

Viale Certosa, 10

27100 Pavia

Italy

This leaflet was last revised in August 2026

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Voriconazole must not be diluted with 4.2% sodium bicarbonate infusion. The following information is intended for healthcare professionals only:

Prior to use this medicine does not require any special temperature storage conditions. Store in the original package in order to protect from light. Required volumes of 10 mg/ml Voriconazole Concentrate

Voriconazole is a single dose unpreserved sterile lyophile.

The compatibility of Voriconazole with diluents other than listed above (or listed below under ‘Incompatibilities’) is unknown.

Stability after reconstitution:

Voriconazole 200 mg powder for solution for infusion

Chemical and physical in-use stability has been demonstrated for 36 hours at 2°C to 8° C for the reconstituted solution.

Incompatibilities:

Body Weight (kg)

Voriconazole must not be infused into the same line or cannula concomitantly with other drug infusions, including parenteral nutrition (e.g. Aminofusin 10% Plus).

voriconazole

dosedosedosedosedose

Stability after dilution:

(number of vials)(number of vials)(number of vials)(number of vials)(number of vials)

Reconstitution and dilution information

Chemical and physical stability of the diluted solutions for infusion has been demonstrated for 36 hours at 2°C to 8°C followed by 3 hours at room temperature.

Voriconazole powder for solution for infusion needs to first be reconstituted with either 19 ml of water for injections or 19 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to obtain an extractable volume of 20 ml of clear concentrate containing 10 mg/ml voriconazole.

Infusions of blood products must not occur simultaneously with Voriconazole.

10-4.0 ml (1)-8.0 ml (1)9.0 ml (1)
15-6.0 ml (1)-12.0 ml (1)13.5 ml (1)

Infusion of total parenteral nutrition can occur simultaneously with Voriconazole but not in the same line or cannula.

20-8.0 ml (1)-16.0 ml (1)18.0 ml (1)

From a microbiological point of view, once reconstituted, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C (in a refrigerator), unless reconstitution has taken place in controlled and validated aseptic conditions.

25-10.0 ml (1)-20.0 ml (1)22.5 ml (2)

It is recommended that a standard 20 ml (non-automated) syringe be used to ensure that the exact amount (19.0 ml) of water for injections or of sodium chloride 9 mg/ml (0.9%) solution for injection is dispensed.

309.0 ml (1)12.0 ml (1)18.0 ml (1)24.0 ml (2)27.0 ml (2)
3510.5 ml (1)14.0 ml (1)21.0 ml (2)28.0 ml (2)31.5 ml (2)
4012.0 ml (1)16.0 ml (1)24.0 ml (2)32.0 ml (2)36.0 ml (2)

After reconstitution with 19 ml of water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection, a clear solution is obtained.

4513.5 ml (1)18.0 ml (1)27.0 ml (2)36.0 ml (2)40.5 ml (3)
5015.0 ml (1)20.0 ml (1)30.0 ml (2)40.0 ml (2)45.0 ml (3)
5516.5 ml (1)22.0 ml (2)33.0 ml (2)44.0 ml (3)49.5 ml (3)

Compatible infusion solutions:

The reconstituted solution can be diluted with:

The required volume of the reconstituted concentrate is then added to a recommended compatible infusion solution listed below to obtain a final Voriconazole solution containing 0.5 to 5 mg/ml of voriconazole.

This medicinal product is for single use only and any unused solution should be discarded and only clear solutions without particles should be used.

Not for administration as a bolus injection.

6018.0 ml (1)24.0 ml (2)36.0 ml (2)48.0 ml (3)54.0 ml (3)
6519.5 ml (1)26.0 ml (2)39.0 ml (2)52.0 ml (3)58.5 ml (3)
7021.0 ml (2)28.0 ml (2)42.0 ml (3)--
7522.5 ml (2)30.0 ml (2)45.0 ml (3)--
8024.0 ml (2)32.0 ml (2)48.0 ml (3)--
8525.5 ml (2)34.0 ml (2)51.0 ml (3)--
9027.0 ml (2)36.0 ml (2)54.0 ml (3)--
9528.5 ml (2)38.0 ml (2)57.0 ml (3)--

Sodium chloride 9 mg/ml (0.9%) solution for injection

Compound sodium lactate intravenous infusion

5% glucose and lactated ringer’s intravenous infusion

5% glucose and 0.45% sodium chloride intravenous infusion 5% glucose intravenous infusion

5% glucose in 20 mEq potassium chloride intravenous infusion 0.45% sodium chloride intravenous infusion

5% glucose and 0.9% sodium chloride intravenous infusion

10030.0 ml (2)40.0 ml (2)60.0 ml (3)--

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 15413/0094

Last revision stated in the text: August 2026 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Voriconazole Hikma 200 mg powder for solution for infusion

What these facts mean

Active substance? Voriconazole
Strength? 200 mg
Drug group (ATC)?
  1. J Antiinfectives for systemic use
    1. J02 Antimycotics for systemic use
      1. J02A Antimycotics for systemic use
        1. J02AC Triazole derivatives, systemic antimycotics
          1. J02AC03 voriconazole
Marketing authorisation? PLGB 15413/0094

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.